Fabry Disease: Effective Tissue Substrate Depletion Following Enzyme Replacement in Α-Galactosidase a Deficient Mice. • 607

Pediatric Research - United States
doi 10.1203/00006450-199704001-00627
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Co-Administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human Α-Galactosidase a Tissue Uptake and Improves Substrate Reduction in Fabry Mice

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2012English

Adipocytes Participate in Storage in Α-Galactosidase Deficiency (Fabry Disease)

Journal of Inherited Metabolic Disease
Genetics
2010English

Receptor-Mediated Endocytosis of Α-Galactosidase a in Human Podocytes in Fabry Disease

PLoS ONE
Multidisciplinary
2011English

Replacement of Α-Galactosidase a in Fabry Disease: Effect on Fibroblast Cultures Compared With Biopsied Tissues of Treated Patients

Virchows Archiv
MedicineForensic MedicinePathologyCell BiologyMolecular Biology
2008English

Fabry Disease: Twenty Novel Α-Galactosidase a Mutations Causing the Classical Phenotype

Journal of Human Genetics
Genetics
2001English

Renal Aspects and Enzyme Replacement Therapy of Fabry Disease

2011English

Fabry Disease: Twenty Novel Α-Galactosidase a Mutations and Genotype-Phenotype Correlations in Classical and Variant Phenotypes

Molecular Medicine
Molecular MedicineGeneticsMolecular Biology
2002English

Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients With Fabry Disease

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2018English

Alpha-Galactosidase a p.A143T, a Non-Fabry Disease-Causing Variant

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy